www.tickerreport.com ·
skye bioscience nasdaqskye releases quarterly earnings results misses expectations by 0 03 eps
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedSkye Bioscience, a biotech developing cannabinoid modulators for ocular diseases, missed earnings estimates by $0.03. The miss is small and the company is pre-revenue, so no direct commercial mechanism on product prices or supply chains. Impact is limited to equity valuation and investor sentiment for this single small-cap biotech. No sector-wide implications.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Skye Bioscience reported EPS of ($0.32), missing consensus of ($0.29) by $0.03.
- SKYE shares opened at $0.88, market cap $30.91 million.
- 52-week low $0.57, high $5.75.
- Two Sigma Investments LP raised holdings by 46.2%.
- Vanguard Group Inc. increased ownership by 5.3%.
Skye Bioscience shares may decline 1-2% in 24-48h due to earnings miss.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- PHARMA_BIOTECHshort